Why the study?
Should stroke alone be chosen as the primary endpoint in antiplatelet trials for patients with recent cerebrovascular events?
Population
Patients with stroke or TIA in antiplatelet clinical trials
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Stroke-only endpoints may refine antiplatelet trial accuracy in recent cerebrovascular events; leaves open whether composites should be deprioritized in future designs.
Structured PICO
Should stroke alone be chosen as the primary endpoint in antiplatelet trials for patients with recent cerebrovascular events?
P
Population
Patients with stroke or TIA in antiplatelet clinical trials
I
Intervention
Antiplatelet therapy
O
Outcome
Choice of primary endpoint (stroke alone vs. composite endpoints)
For patients with recent stroke or TIA, using stroke alone as the primary endpoint in antiplatelet trials provides a more accurate determination of therapeutic benefit than composite endpoints.
Cite This Study
Gregory W. Albers (2000) studied this question.